Bright Minds Biosciences
DRUG
31 hedge funds and large institutions have $176M invested in Bright Minds Biosciences in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
76,662% more capital invested
Capital invested by funds: $230K → $176M (+$176M)
2,500% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 1
417% more funds holding
Funds holding: 6 → 31 (+25)
76.25% more ownership
Funds ownership: 4.29% → 80.54% (+76%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$37.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$17.9M |
| 3 |
CC
Commodore Capital
New York
|
+$17.6M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.2M |
| 5 |
SCM
Sio Capital Management
New York
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$6.31M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$171K |
| 3 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
-$117 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
National Bank of Canada
Montreal,
Quebec, Canada
| $3.31K | -$171K | -4,867 | -98% |
|
|
SS
27
SBI Securities
Tokyo,
Japan
| $1.98K | +$1.94K | +55 | New |
|
28
US Bancorp
Minneapolis,
Minnesota
| $937 | +$915 | +26 | New |
|
|
RS
29
R Squared
Central,
Hong Kong
| $360 | +$352 | +10 | New |
|
30
BlackRock
New York
| $36 | – | – | – |
|
31
Citigroup
New York
| $36 | +$35 | +1 | New |
|
|
APC
32
Aspire Private Capital
Cornelius,
North Carolina
| – | -$117 | -100 | Closed |
|
DRUG Hedge Fund Activity: Q4 2024 in Review
31 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q4 2024, worth a combined $176M — up 76,662% from $230K a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DRUG positions and 1 closed out — a net gain of 25 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $37.3M. The largest seller was AdvisorShares Investments, cutting an estimated $6.31M.
- 31 institutional investors held Bright Minds Biosciences (DRUG) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $176M of Bright Minds Biosciences stock for Q4 2024, up 76,662% quarter-over-quarter.
- 26 funds opened new Bright Minds Biosciences positions in Q4 2024 and 1 closed out, a net change of +25 holders.
- The largest Bright Minds Biosciences buyer in Q4 2024 was Cormorant Asset Management, an estimated $37.3M added.
- The largest Bright Minds Biosciences seller in Q4 2024 was AdvisorShares Investments, an estimated $6.31M sold.
Based on aggregated 13F filings for Q4 2024.